In vitro effects of dual wavelength photobiomodulation on monocytic response in painful temporomandibular disorder

Temporomandibular disorders (TMD) are a prevalent source of chronic pain and disability, yet current therapies often provide limited relief with notable side effects. Photobiomodulation (PBM) has emerged as a promising non-pharmacologic approach to modulate inflammation and pain. This study investigated the effects of a dual-wavelength PBM protocol (laser + light-emitting diode (LED)) on the lipopolysaccharide (LPS)-stimulated monocyte response from individuals with painful TMD. Monocytes were isolated from 16 individuals with TMD enrolled in a randomized, placebo-controlled clinical trial (NCT05916235). Cells were plated into 96-well plates and divided into Control, LPS, and LPS + PBM treatment groups. Monocytes received four alternating-day treatments with two PBM probes: a laser probe (810/660 nm, 180 J/cm²) and an LED probe (660/850 nm). Cytokine and chemokine levels in culture supernatants were measured via multiplexed immunoassays. To verify cell viability after PBM treatment, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used. Statistical analysis was conducted using one-way analysis of variance (ANOVA) with Bonferroni correction, and p < 0.05 was considered significant. PBM significantly reduced levels of pro-inflammatory mediators interleukin-1 beta (IL-1β) (p = 0.005), C-X-C motif chemokine ligand 9 (CXCL9) (p = 0.0042), interferon gamma–induced protein 10 (IP-10) (p = 0.001), and tumor necrosis factor-alpha (TNF-α) (p = 0.0003), while increasing expression of regulatory mediators interleukin-10 (IL-10) (p = 0.0009), interleukin-1 receptor antagonist (IL-1RA) (p = 0.004), and CC motif chemokine ligand 17 (CCL17) (p = 0.003).These findings suggest that the dual-wavelength PBM protocol was able to shift the monocyte immune response from a more pro-inflammatory (M1) phenotype to a more anti-inflammatory, tissue-repair (M2) cytokine profile. These results provide additional evidence for PBM as a benign and non-invasive technique to control and potentially modify TMD-related inflammation. ClinicalTrials.gov ID: NCT05916235.

Temporomandibular disorder; Photobiomodulation; Monocytes; Cytokines; Inflammation

[1] National Institute of Dental and Craniofacial Research. Temporomandibular Disorders and Jaw Pain. 2025. Available at: https://www.nidcr.nih.gov/research/data-statistics/temporomandibular-disorders-jaw-pain (Accessed: 27 May 2025).

[2] The Lewin Group. Study of the per-patient cost and efficacy of treatment for tempormandibular joint disorders. 2001. Available at: https://tmj.org/wp-content/uploads/2020/08/AHRQ1.pdf (Accessed: 27 May 2025).

[3] National Academies of Sciences, Engineering, and Medicine. Temporomandibular disorders: priorities for research and care. The National Academies Press: Washington, DC. 2020.

[4] Leyane TS, Jere SW, Houreld NN. Effect of photobiomodulation at 830 nm on gene expression correlated with JAK/STAT signalling in wounded and diabetic wounded fibroblasts in vitro. Journal of Biophotonics. 2024; 17: e202300230.

[5] Maghfour J, Ozog DM, Mineroff J, Jagdeo J, Kohli I, Lim HW. Photobiomodulation CME part I: overview and mechanism of action. Journal of the American Academy of Dermatology. 2024; 91: 793–802.

[6] Khalil M, Hamadah O, Saifo M, Khalil H, Adi M, Alabeedi F, et al. Effect of photobiomodulation on salivary cytokines in head and neck cancer patients with oral mucositis: a systematic review. Journal of Clinical Medicine. 2024; 13: 2822.

[7] Luitel B, Duggisani T, Luitel A, LaRocco J. Reviewing the efficiency of photobiomodulation therapy in oncological treatment. Frontiers in Oncology. 2024; 14: 1447653.

[8] Fan T, Li Y, Wong AYL, Liang X, Yuan Y, Xia P, et al. A systematic review and network meta‐analysis on the optimal wavelength of low‐level light therapy (LLLT) in treating knee osteoarthritis symptoms. Aging Clinical and Experimental Research. 2024; 36: 203.

[9] Zhang R, Qu J. The mechanisms and efficacy of photobiomodulation therapy for arthritis: a comprehensive review. International Journal of Molecular Sciences. 2023; 24: 14293.

[10] Al Balah OF, Rafie M, Osama AR. Immunomodulatory effects of photobiomodulation: a comprehensive review. Lasers in Medical Science. 2025; 40: 187.

[11] Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al.; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. Journal of Oral & Facial Pain and Headache. 2014; 28: 6–27.

[12] Ribeiro-Dasilva MC, Fillingim RB, Wallet SM. Estrogen-induced monocytic response correlates with TMD pain: a case control study. Journal of Dental Research. 2017; 96: 285–291.

[13] Farré-Guasch E, Aliberas JT, Spada NF, de Vries R, Schulten EAJM, Lobbezoo F. The role of inflammatory markers in temporomandibular myalgia: a systematic review. Japanese Dental Science Review. 2023; 59: 281–288.

[14] Pérez S, Rius-Pérez S. Macrophage polarization and reprogramming in acute inflammation: a redox perspective. Antioxidants. 2022; 11: 1394.

[15] Ishida K, Nagatake T, Saika A, Kawai S, Node E, Hosomi K, et al. Induction of unique macrophage subset by simultaneous stimulation with lipopolysaccharide and interleukin-4. Frontiers in Immunology. 2023; 14: 1111729.

[16] Kuninaka Y, Ishida Y, Ishigami A, Nosaka M, Matsuki J, Yasuda H, et al. Macrophage polarity and wound age determination. Scientific Reports. 2022; 12: 20327.

[17] Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nature Reviews. Neuroscience. 2018; 19: 138–152.

[18] Hanna R, Dalvi S, Bensadoun RJ, Benedicenti S. Role of photobiomodulation therapy in modulating oxidative stress in temporomandibular disorders. A systematic review and meta-analysis of human randomised controlled trials. Antioxidants. 2021; 10: 1028.

[19] Alsarhan J, El Feghali R, Alkhudari T, Benedicenti S, Pasquale C. Can photobiomodulation support the management of temporomandibular joint pain? Molecular mechanisms and a systematic review of human clinical trials. Photonics. 2022; 9: 420.

[20] Mazuqueli Pereira ESB, Basting RT, Abdalla HB, Garcez AS, Napimoga MH, Clemente-Napimoga JT. Photobiomodulation inhibits inflammation in the temporomandibular joint of rats. Journal of Photochemistry and Photobiology. B, Biology. 2021; 222: 112281.

[21] Marcolino AM, Hendler KG, Barbosa RI, Neves LMS, Kuriki HU, Dutra RC. Effect of photobiomodulation therapy (660 nm and 830 nm) on carrageenan-induced edema and pain behavior in mice. Brazilian Journal of Pain. 2022; 5: 206–212.

[22] Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017; 4: 337–361.